Jacqueline E. Shea, PhD

Chief Executive Officer


Message from the CEO

In August 2015, I took the helm as Aeras’s new CEO, guiding the organization in our mission of developing new, effective and safe tuberculosis (TB) vaccines that are affordable and accessible to all who need them. I feel honored to work alongside our dedicated staff and many partners in this endeavor.

This is a challenging time for TB research. In 2015, the world faced the painful truth that despite progress and some successes, our current efforts to fight TB won’t meet our goal to end the epidemic by 2030. All too predictably, TB is now once again recognized as the leading cause of death due to a single infectious disease, taking the lives of 1.8 million people in 2015, according to the World Health Organization (WHO). We simply cannot accept losing so many lives and suffering the devastating impact TB has on patients, families and communities year after year. Doing so would not only be tragic for those suffering from TB, it would pose a major and escalating health risk for the entire world. Accepting the status quo will lead to more instances of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the most dangerous forms of the disease and the most difficult and expensive to treat.

While the world continues to need new TB drugs and diagnostics, it’s important to acknowledge that – as for most infectious diseases – an effective, safe, accessible and affordable vaccine will be essential to TB elimination. It’s this urgent need for a new vaccine that drives us in our work. Our initial research focus is to develop a vaccine to prevent TB disease in adolescents and adults, who bear much of the burden of the disease and are the primary transmitters of TB. We are also committed to the important issue of global access to new TB vaccines and ensuring that the vaccines we develop meet the needs of the many communities affected by this devastating disease.

Significant progress is being made in TB vaccine development by applying the lessons learned from previous preclinical and clinical studies to ongoing work. There are new candidates entering the pipeline bringing a greater diversity of approaches, more rigorous candidate selection and a greater emphasis on developing new tools for TB vaccine discovery and development. Data will also become available from later stage clinical trials over the next few years, which together with ongoing work, could provide significant new insights to inform future vaccine development work.

Yet progress continues to be hampered by limited funding for this important work. As committed as we are to advancing TB vaccine science, we all need to recognize a major and continuing challenge: funding. As a major global infectious disease killer, R&D for TB remains woefully underfunded in relation to its impact. In 2014 only an estimated US $112 million in funding was invested in TB vaccine R&D, almost insignificant when compared to the annual global cost burden of TB, estimated at $20 billion.1, 2

When West Africa experienced an outbreak of Ebola in 2014, the world took much needed action. Policy-makers took notice, emergency research funding was granted and ground-breaking new partnerships formed to rapidly progress development of potential vaccines. If that level of political will and pan-organizational commitment were given to TB – an existing and much more deadly epidemic in terms of lives currently lost per year – the effect could be transformational.

I would like to thank Tom Evans, our previous CEO, for his many contributions to Aeras and the TB vaccine field over the past five years. I would also like to thank all of the generous donors who support our work, our many partners, the participants in our clinical studies and the supportive communities in which our studies take place. I am confident that together, we can and will end TB through new safe, effective, affordable and accessible vaccines.

Jacqueline E. Shea, PhD
Chief Executive Officer

1. WHO. Global Tuberculosis Report 2016
2. WHO. Trade, foreign policy, diplomacy and health; Tuberclosis Control.

Progress, Challenges and Future Direction

Aeras is committed to achieving our goal of developing new, safe, more effective and accessible TB vaccines. Given the current limited pipeline of candidates in efficacy testing, there remains much to do to be confident of success. Looking forward to 2016 and beyond, Aeras will be working with partners to address the scientific challenges and advance the TB vaccine field in several ways, including:

  • Intensifying efforts to identify immune correlates of risk and protection against TB disease and infection by Mycobacterium tuberculosis (Mtb), the bacterium that causes TB
  • Identifying and developing vaccine candidates capable of generating a greater diversity of immune responses than those generated by the candidates currently in the clinical pipeline
  • Diversifying vaccine administration strategies, including aerosol administration, heterologous serial boosting, and adjuvant co-administration
  • Optimizing animal challenge models capable of providing a more accurate assessment of the likelihood of vaccine efficacy in humans
  • Developing new tools, such as a controlled human infection model and a functional assay, that could prove transformational in improving the efficiency and increasing the probabilities of success for TB vaccine candidate development
  • Addressing the critical need for more funding to support TB vaccine research and development by pursuing new and innovative strategies capable of generating a broader base of financial support


TB Threat

TB Killed 1.8 million People in 2015 – More Than Any Other Single Infectious Disease

As an airborne infectious disease, TB can be spread by coughing, speaking and even singing. While most cases of TB can be treated and cured, about one-third of TB patients go undiagnosed, and current treatment side effects can be difficult for patients.

In 2015, global leaders came together to build on the previous Millennium Development Goal (MDG) of halting and reversing TB incidence, to establish the new Sustainable Development Goals (SDGs), including a target to end the TB epidemic by 2030. The WHO, a leader in the fight against TB, has pointed to the need for new TB vaccines to meet this goal.

The serious threat of MDR- and XDR-TB is starting to gain much-needed attention by policymakers. In 2015, the U.K. continued its important work examining the risk of antimicrobial resistance (AMR) with its Review on Antimicrobial Resistance, which, led by economist Jim O’Neill, has published a series of reports analyzing the problem and proposing concrete solutions. The report draws specific attention to the threat of MDR- and XDR-TB, noting that drug resistant-TB is a top AMR threat, alongside malaria and E.coli. This year, the White House also addressed this urgent need when it released its National Action Plan for Combating Multidrug-Resistant Tuberculosis, an important step in the U.S. government’s response to this deadly infectious disease.

Yet, this deadly disease still does not receive the global attention and research funding it requires.

That must change. According to the WHO, we won’t be able to end TB until we develop a new effective and affordable vaccine, together with improved treatments and diagnostic tools. And that’s going to take time, funding and a commitment to strengthen TB research.


TB Fast Facts

New cases of active TB in 2015:10.4 million1
Deaths from TB in 2015:1.8 million1
Approximate deaths from TB per day:4900
Length of treatment:
      Drug-sensitive TB:6 months2
      Drug-resistant TB:18 – 24 months2
Average cost of treatment in U.S.:
      Drug-sensitive TB:$17,000 per person2
      Drug-resistant TB:$150,000 – 480,000 per person2
Total global cost of current TB control:$8 billion1
Economic impact from lost productivity and wages:$12 billion3
Investment needed to develop new TB vaccine:$250 million per year4

1. WHO. Global TB Report 2016
2. CDC. Costly Burden of Drug-Resistant TB in the U.S.
3. WHO. Trade, foreign policy, diplomacy and health; Tuberclosis Control.
4. Stop TB Partnership. The Global Plan to End TB 2016-2020


R&D: Making New TB Vaccines a Reality

In 2015, Aeras and our partners made significant progress toward our goal of developing new TB vaccines to help end the TB epidemic. We placed increased emphasis on exploring new vaccine concepts and diversifying the pipeline, developing robust preclinical models to screen vaccine candidates, exploring innovative clinical trial designs to streamline vaccine development and de-risk candidates at earlier stages of development, and initiating experimental medicine studies to answer fundamental questions on immunity to Mtb to inform vaccine development.

Global TB Vaccine Pipeline


Clinical Work: Faster, Less Costly Clinical Trials

Aeras works with the TB vaccine community to ensure later-stage clinical trials are conducted in the most cost-effective and efficient way possible. Aeras has successfully led initiatives resulting in innovative trials that take less time, require fewer participants and are not as costly, with the aim of determining as early as possible which vaccine candidates should move forward into larger, late stage clinical trials. These innovative trial designs are particularly important as the TB vaccine field’s resources are limited.


Highlights From Our Clinical Work in 2015

Prevention of Infection Trials

The first example of this new methodology is the clinical trial of the H4:IC31 vaccine candidate, which is being developed in partnership with Sanofi Pasteur, under a license from Statens Serum Institut (SSI). This study, currently being conducted in collaboration with the South African Tuberculosis Vaccine Initiative (SATVI) among 990 adolescents in South Africa, is the first-ever Prevention of (established) Infection (POI) trial of a new TB vaccine. This study also includes an arm evaluating if re-vaccination with the BCG vaccine could prevent established Mtb infection in high-risk adolescents within a South African setting. By testing for establishment of Mtb infection, rather than waiting for disease to occur, this novel trial design will allow us to obtain data earlier, with fewer subjects. Prevention of established infection is an important marker of biologically relevant effect, so this type of study can generate data that may fast-track and decrease the risk in TB vaccine research and development. The final analysis of results is expected by early 2018.

Efficacy Study in High-Burden Areas

A further novel trial design which Aeras developed with our partner, GSK, is being used to evaluate efficacy of the GSK vaccine candidate, M72/AS01E. This Phase 2b efficacy study is being conducted among adults who are Mtb-infected (QuantiFERON positive) in African countries that bear some of the highest burdens of TB. This study is on track to provide a primary analysis in 2017, with final results expected in late 2018 or early 2019.

Moving the Field Forward: Assays and Immune Responses

Aeras is collaborating with SSI, Sanofi Pasteur, and the HIV Vaccine Clinical Trial Network on a Phase 1b study to evaluate the safety and immunogenicity of two vaccine candidates (H4:IC31 and H56:IC31), as well as revaccination with the BCG vaccine, in 84 healthy adolescents in Africa. This experimental medicine study with detailed immunological assessment will facilitate identification of assays and immune responses that could be evaluated as potential correlates of protection in efficacy studies with these vaccines. Final results from this study are expected in early 2017.


Pre-clinical Work: A Shift to the Left

Aeras scientists continue to evaluate and advance promising preclinical vaccine candidates through rigorous testing, and by forming groundbreaking collaborations with both academic partners and industry. During 2015, in conjunction with many of our partners in the TB vaccine community, we continued our “shift to the left” with an increased focus on preclinical activities and answering fundamental questions in TB vaccine science. This “shift to the left” approach allows Aeras to focus on building a strong and diverse pipeline of candidates, and to use improved screening models and tools to select the most promising candidates and enable best use of limited resources.

Aeras’s preclinical work is informed by our Scientific Evaluation and Advisory Team (SEAT), which is an important part of our portfolio management process. The SEAT enables us to consider external research proposals, new vaccine concepts and vaccine platform opportunities for additional resource investment. In 2015, the SEAT reviewed 17 submissions and recommended advancement of two of these opportunities.

In June 2015, the Collaboration for TB Vaccine Discovery (CTVD), sponsored by the Bill & Melinda Gates Foundation, was formed to improve collaboration and focus among the diverse groups working on TB vaccine discovery and development. Aeras works closely with the CTVD and is an active member of the CTVD research communities.


Global Efforts

Aeras’s offices around the world allow us to support our global mission and collaborate with international partners. With headquarters in Rockville, Maryland, and offices in Cape Town, South Africa, and Beijing, China, Aeras works with partners around the world to help advance the TB vaccine
R&D field.

Aeras Headquarters: Rockville, Maryland, USA

The Aeras Headquarters in Rockville, Maryland, house Aeras’s organizational leadership and functions – such as human resources, finance and external affairs, as well as our preclinical team and part of our clinical development and clinical operations teams.

Aeras Africa: Cape Town, South Africa

Aeras Africa plays a leading role in preparing and implementing clinical trials, advocating for TB vaccine R&D among policymakers and the media, and engaging with communities suffering from TB. More than one-quarter (26%) of the estimated 10.4 million people who developed TB disease in 2015 were in Africa. In South Africa, TB has remained the leading cause of death for two decades.

Africa is an important region for TB vaccine R&D and Aeras is committed to our strong presence in the region. The high incidence of TB in South Africa, combined with a sophisticated, local biomedical infrastructure and world class research capabilities, means that the region is especially suitable for conducting clinical trials.

Aeras is currently partnering with research institutions in three African countries – South Africa, Kenya and Zambia – to conduct clinical trials, which include trials in Phase 1 and 2 at 15 sites, involving approximately 5,000 participants.

Aeras Asia: Beijing, China

The Asian region is a key priority area for Aeras because of the tremendous TB burden in the Asia Pacific region and the burgeoning biopharma industry there, which could play an important role in developing a new vaccine. Aeras is building partnerships in the region to better understand the epidemic within Asia and work with the best scientists to advance novel vaccines.

More than half (61%) of all TB cases in 2015 occurred in South-East Asia and the Western Pacific, with India, Indonesia and China accounting for 46% of the world’s total TB cases. MDR-TB, which together with extensively drug-resistant TB (XDR-TB) – the most deadly and difficult to treat form of the disease – is most prevalent in this area, with nearly 300,000 new cases in 2015. Extreme poverty in certain regions, an aging population and an increasingly mobile society that can more easily transmit the disease makes the TB threat even greater in the Asia-Pacific region.

Strategically located in Beijing, China, Aeras Asia provides regional integration into the global TB vaccine development strategy. Our staff focuses on identifying and leveraging local regional strengths, capabilities and resources. In 2015, Aeras collaborations in Asia included several epidemiological studies, which are critical to learning more about the TB epidemic in Asia and are an essential first step in preparing for clinical trials.

Other Key Global Efforts in 2015

Conferences & Meetings

  • In April, the Fourth Global Forum on TB Vaccines took place in Shanghai, China—the first time the Forum was held in Asia. Hosted by Fudan University and Shanghai Pulmonary Hospital, with the support of Aeras and TBVI on behalf of the Stop TB Partnership’s Working Group on New Vaccines, the Forum had 290 participants from 34 countries, making it the largest and most geographically diverse event in the series’ history. Aeras Asia discussed resource mobilization with private-sector companies and engaged journalists across the globe to disseminate information about the need for new TB vaccines.
  • Aeras's scientific symposium, “Modelling Dose Responses Following Vaccination: Lessons from the PK/PD Field,” held in May as part of our ongoing series of hot topic conferences in partnership with the National Institute of Allergy and Infectious Diseases, brought together attendees and speakers from all over the world.
  • Our Stakeholders Meeting, held in Cape Town, South Africa, in conjunction with the 46th Union World Conference on Lung Health, addressed more than 50 stakeholders, providing and discussing updates about our progress, programs and strategy.

Scientific Publications

Aeras scientists published 18 scientific articles in peer-reviewed journals, including Vaccine, PLOS One, Tuberculosis, Human Vaccines & Immunotherapeutics and others in 2015.

Community Engagement

Aeras recognizes the critical importance of fully engaging with communities in which our clinical trials take place. As part of our commitment, Aeras Africa launched the TB Vaccine Community Engagement Network (TBVCEN), which is made up of community engagement representatives from each clinical site who meet regularly to share tools, lessons learned and best practices in community engagement to support TB vaccine clinical trials.


Aeras works around the world to raise awareness about the urgent need to invest in TB vaccine R&D and generate support for TB vaccine research and clinical trials. In 2015, Aeras Africa worked with the South African National Department of Health to assist with planning portions of the Union World Conference on Lung Health, which was held in Cape Town in December. Highlights included participating in a number of visits to TB vaccine clinical trial sites by Members of Parliament from around the world. In the U.S., Aeras worked with our advocacy partners to educate Members of Congress about the threat of TB to the U.S. military. Aeras applauds Congress’s decision to restore TB to the group of approved diseases in the Congressionally Directed Medical Research Program’s Peer Reviewed Medical Research Program, which enables Aeras and other TB researchers to apply for funding in 2016.

Media Relations

TB remains a woefully underappreciated threat across much of the world. Aeras therefore works to increase public understanding by collaborating with journalists around the world on articles about the need for new TB vaccines. In 2015, Aeras Africa hosted training sessions for journalists to better understand TB vaccine R&D resulting in several media articles — in collaboration with partners including the International AIDS Vaccine Initiative, AVAC, the HIV Vaccine Trials Network, PATH and the Kenya AIDS NGO’s Consortium. We also participated in two TV panel discussions on South African Broadcasting Corporation, together with experts from the National Department of Health, TB Proof and the WHO, to discuss the importance of TB R&D.


Partnerships Are Essential for Success

Aeras’s work on many of our major activities and initiatives are performed in partnership with others in the field. TB vaccine R&D is complex and costly. No single organization can be successful alone. That’s why we are committed to sharing our knowledge and resources and uniting with other research organizations, academic institutions, funders and policymakers to conquer this disease.


Aeras is grateful to the support of our funders in 2015.

  • The Bill & Melinda Gates Foundation
  • The U.K. Department for International Development
  • The Global Health Innovative Technology Fund
  • Friends of Aeras who supported the organization with gifts to our Annual Fund

Clinical Trial Partners

Aeras appreciates our essential partnerships with the clinical trial sites conducting vaccine studies and their dedicated staff, as well as the individual participants and their communities.

  • The Aurum Institute
  • Be Part Yoluntu Centre
  • The Clinical Infectious Diseases Research Initiative, University of Cape Town
  • CIDRZ (Center for Infectious Disease Research in Zambia)
  • Ekhaya Vac
  • HIV Vaccine Trials Network
  • IMPAACT Network
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Kenya Medical Research Institute
  • Perinatal HIV Research Unit
  • Setshaba Research Centre
  • South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town
  • TASK Applied Science
  • University of Cape Town Lung Institute
  • WITS Reproductive Health & HIV Institute

Academic, Pharmaceutical and Biotech Partners

Aeras works with academic, pharmaceutical and biotech partners to develop TB vaccine candidates. These partnerships are central to Aeras’s mission as a Product Development Partnership.

  • Albert Einstein College of Medicine
  • Biofabri
  • Biomedical Primate Research Centre
  • Centre Hospitalier Universitaire Vaudois
  • China Center for Disease Control and Prevention
  • China National Biotec Group
  • CISM
  • Cornell University
  • Create Vaccine Company, Ltd.
  • Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Dartmouth Geisel School of Medicine
  • European & Developing Countries Clinical Trials Partnership
  • U.S. Food and Drug Administration
  • GSK
  • Harvard University
  • The Institute of Pathogen Biology
  • International AIDS Vaccine Initiative
  • Imperial College London
  • Infectious Disease Research Institute
  • Johns Hopkins University
  • London School of Hygiene & Tropical Medicine
  • Makerere University
  • National Institutes of Biomedical Innovation, Health and Nutrition
  • National Institute of Infectious Disease, Japan
  • New York University
  • Oregon Health & Science University
  • Public Health England
  • Research Council of Norway, Global Health- and Vaccination Research
  • Rutgers University
  • Sanofi Pasteur
  • Statens Serum Institut
  • Stop TB Partnership, Working Group on New Vaccines
  • TuBerculosis Vaccine Initiative
  • Transgene
  • Tsukuba Primate Research Center
  • University of California, Los Angeles
  • University of Bergen
  • University of Maryland
  • University of Oxford
  • University of Pittsburgh
  • University of Wales


About Aeras


Aeras’s mission is to develop safe and effective new TB vaccines that are affordable and accessible to all who need them.


Primary R&D Strategic Goal

Aeras’s primary strategic goal is to develop a new vaccine to prevent TB disease in adolescents and adults as they bear the main burden of TB and are the primary transmitters of disease.

Aeras R&D Strategy

Aeras is committed to serving as a valued, objective and globally recognized partner in translating early-stage discoveries into safe, effective and accessible TB vaccines. Our R&D strategy is to build on recent progress within the field and lessons learned to date to deliver significant progress by 2022, towards developing a TB vaccine capable of preventing TB transmission in adolescents and adults. At a high level, our strategy to achieve this goal is described below:

  1. Increase diversity in the pipeline through innovation
  2. Evaluate CMV-TB candidate(s) as novel TB vaccine(s)
  3. Develop improved and new tools to enable effective identification of the most promising candidates
  4. Use translational and experimental medicine studies and novel trial designs to de-risk candidates at earlier and less costly stages of development
  5. Determine whether any of the current first generation of clinical candidates is a promising TB vaccine or approach
  6. Improve global awareness of the urgent need for new TB vaccines and the requirement for additional funding

Core Values

In pursuit of our mission, Aeras is guided by our core values. These core values express our aspirations and the behaviors we want to exhibit and model. They shape the culture and character of Aeras and inform all of our decisions and actions.


We are committed to high-quality results that make a positive impact in keeping with our mission.


We promote an environment that fosters empowerment, taking initiative and leading by example.


We value teamwork, knowledge sharing and working in partnership – internally and externally – to achieve common goals.


We recognize the dignity of each individual and value the contributions, opinions and expertise of all members of our organization and larger community.


We maintain the highest ethical standards and transparency in our work and in our dealings with our partners, stakeholders and our fellow employees.

2015 Financials

Aeras is committed to strong, effective stewardship of our funds as we pursue our mission and is in good financial health. In June, Aeras divested our manufacturing facilities to IDT Biologika GmbH, allowing us to focus more of our resources on our core strength and mission, TB vaccine development.

  • Revenue

  • Bill & Melinda Gates Foundation Grant$ 28,765,000
  • Other Grant Revenue$ 8,130,632
  • Contract Service$ 616,980
  • Total Revenue$ 37,512,612
100 100 100 100 100 100 100 100 100 100
76 23 1 u
76 23 1 u
76 23 1 u
76 23 1 u
76 23 1 u
76 23 1 u
76 23 1 u
76 23 1 u


  • Expenses

  • Total Vaccine Research Programs$ 32,693,723
  • External & Scientific Affairs$ 3,778,043
  • Support Services$ 6,274,100
  • Contract Resource Sharing$ 1,992,157
  • Total Expenses$ 44,738,023
100 100 100 100 100 100 100 100 100 100
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u
76 9 15 u


  • Other Changes in Net Assets

  • Foreign Currency Loss
    Net of Investment Income
    $ 1,034,996
  • Net Loss on Discontinued Operations*$ 4,053,514

*Discontinued Operations reflect the net financial results of the Aeras Contract Manufacturing and Process Development operations which were sold in 2015 and no longer operated by Aeras effective June 22, 2015. Amount is net of gain on sale of the discontinued operations.

  • Net Assets

  • Change in Net Assets$ 12,313,921
  • Net Assets - Beginning of Year$ 36,897,080
  • Net Assets - End of Year$ 24,583,159

Aeras is grateful to the leaders who contributed to the strength of the organization in 2015.

2015 Board of Directors

Learn More
  • Lota S. Zoth, CPA (Ret)

    Board Chair
    Former CFO of MedImmune, Inc.
    (2011 – present)

  • Barry Bloom, PhD

    Distinguished Service Professor at Harvard University
    (2012 – present)

  • David L. Blumberg

    Former Life Sciences
    Sector Leader of KPMG
    (2015 – present)

  • James Connolly

    Former President & CEO of Aeras
    (2010 – present)

  • Marja Esveld, MSc

    Senior Advisor, Global Health and Innovation
    (2013 – present)

  • Marian Eslie Jacobs, MD

    Former Dean, Faculty of Health Sciences, University of Cape Town
    (2014 – present)

  • Professor Michel Kazatchkine, MD

    Senior Fellow, Global Health Programme, Graduate Institute of International and Development Studies
    (2014 – present)

  • Wayne F. Pisano

    President and CEO, VaxInnate
    (2011 – present)

  • Regina Rabinovich, MD, M.P.H.

    ExxonMobil Malaria Scholar in Residence, Harvard School of Public Health
    (2010 – present)

  • Jacqueline E. Shea, PhD

    CEO of Aeras
    (2015 – present)

  • Gerd Zettlmeissl, PhD

    Former CEO of Intercell AG
    (2011 – present)

2015 Senior Leadership

Learn More
  • Jacqueline E. Shea, PhD

    Chief Executive Officer as of August 12, 2015

  • Thomas G. Evans, MD

    Chief Executive Officer, 2013-2015

  • Ann M. Ginsberg, MD, PhD

    Chief Medical Officer

  • Dara Erck

    Vice President, External Affairs

  • Rita Khanna, PhD, J.D.

    General Counsel

  • Wendy Penry

    Chief Human Resources Officer

  • Daniel Rezikov

    Chief Financial Officer

  • Lew Schrager, MD

    Vice President,
    Science Affairs

  • Dereck Tait, MB, ChB

    Senior Clinical Director & Office Lead,
    Aeras Africa

  • Barry Walker, PhD

    Vice President,
    Preclinical Development

Regional Office Leadership

  • Sharon Chan, DPhil, MBA

    Head of Aeras Asia

  • Dereck Tait, MB, ChB

    Senior Clinical Director & Office Lead,
    Aeras Africa

Advisory Boards

Vaccine Advisory Committee

Aeras’s Vaccine Advisory Committee (VAC) provides external, independent, expert advice on criteria for vaccine candidate selection, preclinical stage-gating and priorities for advancing candidates in preclinical and clinical portfolios. The VAC, which meets at least twice a year, advises Aeras on a broad range of crucial product development issues including: development plans, regulatory strategy, epidemiology studies, innovative clinical trial designs and downstream market considerations.

  • Ann M. Ginsberg, MD, PhD (Secretariat)


  • Marcel Behr, MD

    McGill University

  • Barry Bloom, PhD

    ex officio, Harvard University

  • Ralf Clemens, MD, PhD

    Takeda Pharmaceuticals

  • Patricia E. Fast, MD, PhD


  • Barney S. Graham, MD, PhD

    Vaccine Research Center, NIAID, NIH

  • Willem Hanekom, MB, ChB

    The Bill & Melinda Gates Foundation

  • Tom H. M. Ottenhoff, MD, PhD

    Leiden University Medical Center

  • Rino Rappuoli, PhD

    GSK Vaccines

  • Robin Wood, MD DSC (Med)

    Desmond Tutu HIV Centre Institute of Infectious Disease, University of Cape Town

  • Gerd Zettlmeissl, PhD

    Former CEO, Intercell AG

Biomarkers and Correlates Working Group

The Biomarkers and Correlates Working Group (BCWG) is an external advisory group that advises Aeras on progress in the field of correlates and biomarkers, including gaps and new developments and provides external reviews of other Aeras projects and programs.

  • JoAnne Flynn, PhD (Chair)

    University of Pittsburgh School of Medicine

  • Professor Glyn Hewinson

    Veterinary Laboratories Agency

  • Willem Hanekom, MBChB

    The Bill & Melinda Gates Foundation

  • Stefan H. E. Kaufmann, PhD

    Max Planck Institute for Infection Biology

  • Tom H. M. Ottenhoff, MD, PhD

    Leiden University Medical Center

  • Thomas J. Scriba, PhD

    South African TB Vaccine Initiative

  • Robert A. Seder, MD

    National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center

  • Alan Sher, PhD

    National Institute of Allergy and Infectious Diseases (NIAID)

  • Christine Sizemore, PhD

    Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID)

  • Lewis Schrager, MD

    Aeras (Secretariat)

  • Lynda Stuart, MD, PhD

    The Bill & Melinda Gates Foundation

  • Daniel Zak, PhD

    Center for Infectious Disease Research

Go to aeras.org